Literature DB >> 11847277

Structural insights into human serum albumin-mediated prostaglandin catalysis.

Jinsheng Yang1, Charles E Petersen, Chung-Eun Ha, Nadhipuram V Bhagavan.   

Abstract

Previous studies have shown that many arachidonic acid metabolites bind to human serum albumin (HSA) and that the metabolism of these molecules is altered as a result of binding. The present study attempted to gain insights into the mechanisms by which prostaglandins bound to subdomain 2A of HSA are metabolized by catalytic processes. The breakdown of the prostaglandin 15-keto-PGE(2) to 15-keto-PGA(2) and 15-keto-PGB(2) in the presence of wild-type HSA and a number of subdomain 2A mutants was examined using a previously validated spectroscopic method which monitors absorbance at 505 nm. The species examined using this method were wild-type HSA, K195M, K199M, F211V, W214L, R218M, R218P, R218H, R222M, H242V, R257M, and bovine serum albumin. Previous studies of HSA-mediated catalysis indicated that the breakdown of HSA-bound prostaglandins results from an alkaline microenvironment in the binding site. Our results show that the catalytic breakdown of HSA-bound 15-keto-PGE(2) to 15-keto-PGB(2) results from two specific processes which are modulated by specific amino acid residues. Specifically, some amino acid residues modulate the rate of step 1, the conversion of 15-keto-PGE(2) to 15-keto-PGA(2), while other residues modulate the rate of step 2, the conversion of 15-keto-PGA(2) to 15-keto-PGB(2). Some residues modulate the rate of steps 1 and 2. In total, while our results support the involvement of certain basic amino acid residues in the catabolism of HSA-bound 15-keto-PGE(2), our data suggest that metabolism of HSA-bound prostaglandins may be a more complex and specific process than previously thought.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11847277      PMCID: PMC2373475          DOI: 10.1110/ps.28702

Source DB:  PubMed          Journal:  Protein Sci        ISSN: 0961-8368            Impact factor:   6.725


  32 in total

1.  The three recombinant domains of human serum albumin. Structural characterization and ligand binding properties.

Authors:  M Dockal; D C Carter; F Rüker
Journal:  J Biol Chem       Date:  1999-10-08       Impact factor: 5.157

2.  Modification of human serum albumin with trifluoromethyl-substituted aryl halides and sulfonates.

Authors:  J T Gerig; J D Reinheimer
Journal:  J Am Chem Soc       Date:  1975-01-08       Impact factor: 15.419

3.  Binding of prostaglandin to human serum albumin.

Authors:  W G Unger
Journal:  J Pharm Pharmacol       Date:  1972-06       Impact factor: 3.765

4.  Kinetics of dehydration and isomerization of prostaglandins E 1 and E 2 .

Authors:  D C Monkhouse; L Van Campen; A J Aguiar
Journal:  J Pharm Sci       Date:  1973-04       Impact factor: 3.534

5.  Total rate equation for decomposition of prostaglandin E2.

Authors:  G F Thompson; J M Collins; L M Schmalzried
Journal:  J Pharm Sci       Date:  1973-10       Impact factor: 3.534

6.  Arachidonic acid-induced human platelet aggregation and prostaglandin formation.

Authors:  M J Silver; J B Smith; C Ingerman; J J Kocsis
Journal:  Prostaglandins       Date:  1973-12

7.  Five recombinant fragments of human serum albumin-tools for the characterization of the warfarin binding site.

Authors:  M Dockal; M Chang; D C Carter; F Rüker
Journal:  Protein Sci       Date:  2000-08       Impact factor: 6.725

8.  Familial dysalbuminemic byperthyroxinemia may result in altered warfarin pharmacokinetics.

Authors:  C E Petersen; C E Ha; K Harohalli; D S Park; N V Bhagavan
Journal:  Chem Biol Interact       Date:  2000-02-01       Impact factor: 5.192

9.  Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I.

Authors:  I Petitpas; A A Bhattacharya; S Twine; M East; S Curry
Journal:  J Biol Chem       Date:  2001-04-02       Impact factor: 5.157

10.  Interaction of prostaglandins with blood plasma proteins. Comparative binding of prostaglandins A 2 , F 2 and E 2 to human plasma proteins.

Authors:  A Raz
Journal:  Biochem J       Date:  1972-11       Impact factor: 3.857

View more
  15 in total

1.  Cord blood mesenchymal stem cells suppress DC-T Cell proliferation via prostaglandin B2.

Authors:  Lieke C J van den Berk; Bas J H Jansen; Stuart Snowden; Kim G C Siebers-Vermeulen; Christian Gilissen; Gesine Kögler; Carl G Figdor; Craig E Wheelock; Ruurd Torensma
Journal:  Stem Cells Dev       Date:  2014-04-23       Impact factor: 3.272

2.  Tying up PGE2 with albumin to relieve immunosuppression in cirrhosis.

Authors:  Vicente Arroyo; Richard Moreau
Journal:  Nat Med       Date:  2014-05       Impact factor: 53.440

3.  Regulation of Candida albicans morphogenesis by fatty acid metabolites.

Authors:  Mairi C Noverr; Gary B Huffnagle
Journal:  Infect Immun       Date:  2004-11       Impact factor: 3.441

4.  New site(s) of methylglyoxal-modified human serum albumin, identified by multiple reaction monitoring, alter warfarin binding and prostaglandin metabolism.

Authors:  Michael J Kimzey; Hussein N Yassine; Brent M Riepel; George Tsaprailis; Terrence J Monks; Serrine S Lau
Journal:  Chem Biol Interact       Date:  2010-10-08       Impact factor: 5.192

5.  Characterization of prostaglandin E2 production by Candida albicans.

Authors:  John R Erb-Downward; Mairi C Noverr
Journal:  Infect Immun       Date:  2007-04-30       Impact factor: 3.441

6.  Reactive intermediates: molecular and MS-based approaches to assess the functional significance of chemical-protein adducts.

Authors:  Terrence J Monks; Serrine S Lau
Journal:  Toxicol Pathol       Date:  2012-12-06       Impact factor: 1.902

7.  Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2.

Authors:  Alastair J O'Brien; James N Fullerton; Karen A Massey; Grace Auld; Gavin Sewell; Sarah James; Justine Newson; Effie Karra; Alison Winstanley; William Alazawi; Rita Garcia-Martinez; Joan Cordoba; Anna Nicolaou; Derek W Gilroy
Journal:  Nat Med       Date:  2014-04-13       Impact factor: 53.440

8.  Bile duct-ligated mice exhibit multiple phenotypic similarities to acute decompensation patients despite histological differences.

Authors:  Alastair O'Brien; Louise China; Karen A Massey; Anna Nicolaou; Alison Winstanley; Justine Newson; Adrian Hobbs; Tatsiana Audzevich; Derek W Gilroy
Journal:  Liver Int       Date:  2015-06-22       Impact factor: 5.828

Review 9.  Hemodynamic and Systemic Effects of Albumin in Patients with Advanced Liver Disease.

Authors:  Manuel Tufoni; Maurizio Baldassarre; Giacomo Zaccherini; Agnese Antognoli; Paolo Caraceni
Journal:  Curr Hepatol Rep       Date:  2020-07-01

10.  ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial.

Authors:  Louise China; Nicola Muirhead; Simon S Skene; Zainib Shabir; Roel P H De Maeyer; Alexander A N Maini; Derek W Gilroy; Alastair J O'Brien
Journal:  BMJ Open       Date:  2016-01-25       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.